MT-401
MRKR-19-401
Phase 2 small_molecule terminated
Quick answer
MT-401 for Acute Myeloid Leukemia is a Phase 2 program (small_molecule) at Marker Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Marker Therapeutics
- Indication
- Acute Myeloid Leukemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated